Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells.

Cell Death Dis · 2026 · PMC13039999 · PMID 41794832

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although Ricolinostat treatment showed a trend toward restricting leukemia progression, the results were not statistically significant, indicating that while HDAC6 inhibition enhances T cell-mediated immune responses (Fig. 5J, K ), and its therapeutic benefit in vivo requires additional combination partners.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.